ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug

ImmunityBio Inc. (NASDAQ:IBRX) shares are trading lower on Monday.

The company announced the resubmission of its supplemental Biologics License Application (sBLA) for ANKTIVA to the FDA.

FDA Resubmission

The FDA has acknowledged receipt of ImmunityBio’s sBLA for ANKTIVA® in treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

The resubmission follows ongoing discussions with the FDA that began in January 2026, where the agency requested additional data to support its review, leading to the submission of updated efficacy data in March.

In May 2025, ImmunityBio received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease.

Technical Analysis

ImmunityBio’s stock is currently trading 1.3% below its 20-day simple moving average (SMA) but is 41.3% above its 100-day SMA, indicating a stronger long-term trend.

Over the past 12 months, shares have surged 184.54%, and they are currently positioned closer to their 52-week highs than lows, reflecting strong momentum.

The RSI is at 55.12, which is considered neutral territory, suggesting that the stock is not overbought or oversold at this time.

Meanwhile, MACD is at 1.0302, below its signal line at 1.1909, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that while the stock has shown strength, there may be some caution among traders.

• Key Resistance: $12.50
• Key Support: $7.00

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $12.50. Recent analyst moves include:

• Piper Sandler: Overweight (Raises Target to $12.00) (Mar. 4)
• HC Wainwright & Co.: Buy (Raises Target to $15.00) (Feb. 23)
• D. Boral Capital: Buy (Maintains Target to $23.00) (Feb. 23)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for ImmunityBio, highlighting its strengths and weaknesses compared to the broader market:

• Momentum: Bullish (Score: 98.85) — Stock is outperforming the broader market.

The Verdict: ImmunityBio’s Benzinga Edge signal reveals a strong momentum score, indicating that the stock is currently outperforming the market. Investors should monitor upcoming developments closely, particularly as the company approaches its next earnings report.

Top ETF Exposure

• Virtus LifeSci Biotech Products ETF (NYSE:BBP): 4.03% Weight

IBRX Price Action: ImmunityBio shares were down 1.56% at $8.53 at the time of publication on Monday.

Image via Shutterstock